IDRA News and Press, Idera Pharmaceuticals Inc. From 11/17/20

– COO Role is Key to Preparedness for NDA Filing and Commercial Launch – – Clayton Fletcher , Head of Business Development & Strategic Planning , to Retire – EXTON, Pa., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Idera...

As was reported last year in phase II results, tilsotolimod is effective in combination with Yervoy to treat refractory advanced melanoma. Idera's current capitalization, around $98 million, offers limited downside risk and huge upside potential. Idera offers a good entry opportun...

Idera Pharmaceuticals (IDRA): Q3 GAAP EPS of -$0.59 misses by $0.37.Cash, cash equivalents, and short-term investments of $28.98M.Press Release For further details see: Idera Pharmaceuticals EPS misses by $0.37

EXTON, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today reported its financial and operational results for the third quarter ended September 30, 2020. “Tilsotolimod is the most advance...

Iovance Biotherapeutics, in an attempt to secure FDA-approval for their biologic, lifileucel, in advanced melanoma, was set back as the FDA requires some more information. This can't come to much of a surprise to investors, as Iovance's TIL therapy carries a complex manufacturing and ...

Idera Pharmaceuticals (IDRA) receives patent and is allowed application entitled 'Immune Modulation with TLR9 Agonists for Cancer Treatment' for investigational therapy tilsotolimod.The patents and the allowed application provide exclusivity for certain uses of tilsotolimod through ...

EXTON, Pa., Sept. 28, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,772,907 (the ‘907 Patent) and allowed U.S. Patent Application No. 16/557,597 (the ‘597 Application)...

Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presented AbbVie to present a trial-in-progress poster of ABBV-368 in combination with tilsotolimod in recurrent / metastatic head and neck squamous ce...

The following slide deck was published by Idera Pharmaceuticals, Inc. in conjunction with this Read more ...

Idera Pharmaceuticals (NASDAQ: IDRA ) : Q2 GAAP EPS of -$0.72 misses by $0.33 . More news on: Idera Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...